HRP20030388A2 - Use of antiprogestins for the induction of apoptosis in a cell - Google Patents

Use of antiprogestins for the induction of apoptosis in a cell Download PDF

Info

Publication number
HRP20030388A2
HRP20030388A2 HR20030388A HRP20030388A HRP20030388A2 HR P20030388 A2 HRP20030388 A2 HR P20030388A2 HR 20030388 A HR20030388 A HR 20030388A HR P20030388 A HRP20030388 A HR P20030388A HR P20030388 A2 HRP20030388 A2 HR P20030388A2
Authority
HR
Croatia
Prior art keywords
antiprogestin
cell
tumor
apoptosis
breast cancer
Prior art date
Application number
HR20030388A
Other languages
English (en)
Croatian (hr)
Inventor
Hoffmann Jens
Lichtner Rosemarie
Siemeister Gerhard
Schneider Martin
Fuhrmann Ulrike
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of HRP20030388A2 publication Critical patent/HRP20030388A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20030388A 2000-10-18 2001-10-17 Use of antiprogestins for the induction of apoptosis in a cell HRP20030388A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24099100P 2000-10-18 2000-10-18
EP00250342 2000-10-18
PCT/EP2001/012006 WO2002032432A1 (en) 2000-10-18 2001-10-17 Use of antiprogestins for the induction of apoptosis in a cell

Publications (1)

Publication Number Publication Date
HRP20030388A2 true HRP20030388A2 (en) 2005-04-30

Family

ID=26072952

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030388A HRP20030388A2 (en) 2000-10-18 2001-10-17 Use of antiprogestins for the induction of apoptosis in a cell

Country Status (28)

Country Link
EP (1) EP1326617B9 (https=)
JP (1) JP2004511523A (https=)
KR (1) KR100668024B1 (https=)
CN (1) CN1209111C (https=)
AT (1) ATE334683T1 (https=)
AU (2) AU2002223619B2 (https=)
BG (1) BG107744A (https=)
BR (1) BR0114696A (https=)
CA (1) CA2423020C (https=)
CY (1) CY1105745T1 (https=)
CZ (1) CZ299823B6 (https=)
DE (1) DE60121980T2 (https=)
DK (1) DK1326617T3 (https=)
EA (1) EA010593B1 (https=)
EE (1) EE200300157A (https=)
ES (1) ES2269492T3 (https=)
HR (1) HRP20030388A2 (https=)
HU (1) HUP0301433A3 (https=)
IL (2) IL154976A0 (https=)
MX (1) MXPA03002955A (https=)
NO (1) NO20031741L (https=)
NZ (1) NZ538347A (https=)
PL (1) PL360157A1 (https=)
PT (1) PT1326617E (https=)
SI (1) SI1326617T1 (https=)
SK (1) SK4702003A3 (https=)
UA (1) UA76729C2 (https=)
WO (1) WO2002032432A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
WO2008128786A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
EP2136796A2 (en) * 2007-04-23 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca-mediated cancer alone or as combination with antiestrogen
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
JP6092880B2 (ja) * 2011-10-04 2017-03-08 インヴァイヴィス ファーマスーティカルズ インコーポレーテッドＩｎｖｉｖｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 抗プロゲスチン感受性腫瘍を特定および治療する方法ならびに系

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
EP1326617B9 (en) 2006-10-25
ES2269492T3 (es) 2007-04-01
EA010593B1 (ru) 2008-10-30
IL154976A0 (en) 2003-10-31
DK1326617T3 (da) 2006-12-18
CZ299823B6 (cs) 2008-12-03
EE200300157A (et) 2003-08-15
DE60121980D1 (de) 2006-09-14
HK1062273A1 (en) 2004-10-29
MXPA03002955A (es) 2003-08-07
DE60121980T2 (de) 2007-03-01
IL154976A (en) 2007-05-15
EA200300479A1 (ru) 2003-10-30
EP1326617A1 (en) 2003-07-16
CA2423020A1 (en) 2002-04-25
HUP0301433A2 (hu) 2003-10-28
ATE334683T1 (de) 2006-08-15
KR100668024B1 (ko) 2007-01-15
CA2423020C (en) 2009-01-20
BG107744A (bg) 2004-02-27
CN1209111C (zh) 2005-07-06
UA76729C2 (uk) 2006-09-15
NO20031741L (no) 2003-06-17
CY1105745T1 (el) 2010-12-22
WO2002032432A1 (en) 2002-04-25
PL360157A1 (en) 2004-09-06
EP1326617B1 (en) 2006-08-02
NZ538347A (en) 2007-03-30
SI1326617T1 (sl) 2007-02-28
PT1326617E (pt) 2006-12-29
BR0114696A (pt) 2003-11-18
SK4702003A3 (en) 2004-01-08
AU2002223619B2 (en) 2006-08-24
AU2361902A (en) 2002-04-29
HUP0301433A3 (en) 2010-01-28
KR20030057540A (ko) 2003-07-04
NO20031741D0 (no) 2003-04-15
CN1469749A (zh) 2004-01-21
JP2004511523A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
DE60216630T2 (de) Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
US8048869B2 (en) Pharmaceutical composition for use in hormone replacement therapy
HU221589B (hu) Emlő- és méhrák kezelésére alkalmas kombinációs gyógyszerkészítmény és eljárás előállítására
MX2010011272A (es) Antagonistas de la progesterona tales como cdb-4124 en el tratamiento de la endometriosis fibrosis uterina, disminorrea, cancer del seno, etc.
JP2010077158A (ja) ホルモン−依存性疾病の予防及び処理のための抗黄体ホルモンの使用
KR20090067198A (ko) 자궁내막 증식을 억제하는 조성물과 방법
CN100374116C (zh) 用于癌症治疗的含有雌四醇衍生物的药物组合物
HRP20030388A2 (en) Use of antiprogestins for the induction of apoptosis in a cell
US20040072811A1 (en) Use of antiprogestins for the induction of apoptosis in a cell
AU2002223619A1 (en) Use of antiprogestins for the induction of apoptosis in a cell
KR20030044006A (ko) 종양 세포의 성장 인자 의존성의 저해
TWI306403B (en) Use of antiprogestings for the induction of apoptosis in a cell
DiPasquale et al. Action of an estradiol-17β antagonist in intact, ovariectomized, hypophysectomized and hypophysectomized-ovariectomized rats
HK1062273B (en) Use of antiprogestins for the induction of apoptosis in a cell
UA75615C2 (en) Use of antiprogestins for preventing or treating hormone-dependent diseases
HK1071697B (en) Inhibition of the growth factor dependency of tumor cells
HK1225606A1 (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer
HK1225606A (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer
HK1155085A (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

ODBI Application refused